Remission Through Early Monitored Insulin Therapy - Duration Month

• Status: Completed
• Trial end date: 2020-07-31
• Target enrollment: 0
• Participant gender: All

Summary

REMIT-DM is a feasibility pilot study where participants will be recruited soon after their diagnosis of type 2 diabetes to be placed immediately on insulin therapy for maximum of four weeks with titrations of insulin guided by glucose levels and trends provided by a continuous glucose monitor (CGM), with the purpose of achieving diabetes remission.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sandra Sobel
• Treatments: Insulin; Insulin Glargine; Insulin Lispro; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

1. Age ≥18

2. A1C criteria - >7.0

3. Newly diagnosed with T2D within 4 years

4. Lifestyle controlled

5. Subject may be on up to 2 medications for diabetes.

6. Smart phone or home computer compatible with DEXCOM CLARITY software

7. English speaking

8. Assessed by endocrinologist and diabetes educator to be able to perform skills necessary for CGM use and insulin delivery

Exclusion Criteria:

1. Autoimmune Type 1 DM, defined as positive GAD65 or islet cell antibodies

2. Pregnant

3. Chronic Kidney Disease (CKD) Stage IV or greater

4. Mental and/or cognitive disorder (based on documented disorder and/or assessment of physician or educator)

5. No access to computer for downloading CGM

6. BMI <18.0